Pluto Biosciences, Inc

GSE151803: Identification of Lead Drug Candidates for COVID-19 based on Drug Screening Using Human Pluripotent Stem Cell-Derived Cells/Organoids

Bulk RNA sequencing

We systematically probed which cell types are permissive to SARS-CoV-2 infection. Transcriptomic analysis following SARS-CoV-2 infection of hPSC-derived pancreatic and lung organoids revealed upregulation of chemokines but not type I/III interferon signaling, similar to what was seen in primary human COVID-19 pulmonary infection. SOURCE: David Redmond (dar2042@med.cornell.edu) - Weill Cornell Medicine

View this experiment on Pluto Biosciences, Inc